Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 4 de 4
Filter
Add more filters










Database
Language
Publication year range
1.
J Prim Care Community Health ; 14: 21501319231162482, 2023.
Article in English | MEDLINE | ID: mdl-37056032

ABSTRACT

INTRODUCTION: Families and friends of homicide victims (FFHV) interact with healthcare systems almost immediately after the traumatic event. Their interactions with healthcare providers can either facilitate healing, have a neutral effect, or compound an already painful experience. When trauma victims are admitted to the hospital, resources are necessarily diverted on their behalf with less consistent attention paid to their families and friends. The interactions surrounding the immediate circumstance as well as experiences in the weeks to months after can have significant long-term impact. This study explores the needs and experiences of FFHV when interacting with the healthcare system to inform physicians' and providers' interactions and provision of services. METHODS: This study of 3 focus groups sought to understand these experiences with the healthcare system to better inform physicians' and providers' interactions and provision of services. RESULTS: Using the framework approach, the study ultimately built upon the existing trauma-informed care (TIC) framework to include several emergent themes. Participants discussed the need for death notification sensitivity, benefits of coordinated care, barriers to accessing care, the need for physician empathy and attention, the lack of trauma screening, and hastily prescribing medications. CONCLUSION: This TIC approach can inform future healthcare interactions with the FFHV as it grounds the patients' experience in their historical reality and may improve future provider-patient relationship.


Subject(s)
Friends , Physicians , Humans , Homicide , Delivery of Health Care , Health Personnel
2.
Mayo Clin Proc ; 89(10): 1436-51, 2014 Oct.
Article in English | MEDLINE | ID: mdl-24974260

ABSTRACT

The prevalence of skin and soft tissue infections (SSTIs) has been increasing in the United States. These infections are associated with an increase in hospital admissions. Hospitalists play an increasingly important role in the management of these infections and need to use hospital resources efficiently and effectively. When available, observation units are useful for treating low-risk patients who do not require hospital admission. Imaging tools may help to exclude abscesses and necrotizing soft tissue infections; however, surgical exploration remains the principal means of diagnosing necrotizing soft tissue infections. The most common pathogens that cause SSTIs are streptococci and Staphylococcus aureus. Methicillin-resistant S aureus (MRSA) is a prevalent pathogen, and concerns are increasing regarding the unclear distinctions between community-acquired and hospital-acquired MRSA. Other less frequent pathogens that cause SSTIs include Enterococcus species, Escherichia coli, Klebsiella species, Enterobacter species, and Pseudomonas aeruginosa. Cephalexin and clindamycin are suitable options for infections caused by streptococcal species and methicillin-susceptible S aureus. The increasing resistance of S aureus and Streptococcus pyogenes to erythromycin limits its use in these infections, and better alternatives are available. Parenteral cefazolin, nafcillin, or oxacillin can be used in hospitalized patients with nonpurulent cellulitis caused by streptococci and methicillin-susceptible S aureus. When oral MRSA therapy is indicated, clindamycin, doxycycline, trimethoprim-sulfamethoxazole, or linezolid is appropriate. Vancomycin, linezolid, daptomycin, tigecycline, telavancin, and ceftaroline fosamil are intravenous options that should be used in MRSA infections that require patient hospitalization. In the treatment of patients with SSTIs, hospitalists are at the forefront of providing proper patient care that reduces hospital costs, duration of therapy, and therapeutic failures. This review updates guidelines on the management of SSTIs with a focus on infections caused by S aureus, particularly MRSA, and outlines the role of the hospitalist in the effective management of SSTIs.


Subject(s)
Anti-Bacterial Agents/therapeutic use , Community-Acquired Infections/epidemiology , Skin Diseases, Bacterial/drug therapy , Soft Tissue Infections/drug therapy , Community-Acquired Infections/drug therapy , Global Health , Hospitalists , Humans , Morbidity/trends , Skin Diseases, Bacterial/epidemiology , Soft Tissue Infections/epidemiology
3.
Postgrad Med ; 126(2): 18-29, 2014 Mar.
Article in English | MEDLINE | ID: mdl-24685965

ABSTRACT

Community-acquired bacterial pneumonia (CABP) is an important health care concern in the United States and worldwide, and is associated with significant morbidity, mortality, and health care expenditure. Streptococcus pneumoniae is the most frequent causative pathogen of CABP. Other common pathogens include Staphylococcus aureus, Haemophilus influenzae, Enterobacteriaceae, Legionella pneumophila, Mycoplasma pneumoniae, and Chlamydophila pneumoniae. However, in clinical practice, the causative pathogen of CABP is most often not identified. Therefore, a common treatment approach for patients hospitalized with CABP is empiric antibiotic therapy with a ß-lactam in combination with a macrolide, respiratory fluoroquinolones, or tetracyclines. An increase in the incidence of S. pneumoniae that is resistant to frequently used antibiotics, including ß-lactams, macrolides, and tetracyclines, provides a challenge for the physician when selecting empiric antimicrobial therapy. When patients with CABP do not respond to initial therapy, they must be adequately reevaluated with further diagnostic testing, change in antimicrobial regimen, and/or transfer of the patient to a higher level of care. The role of hospital medicine physicians is crucial in treating patients who are hospitalized with CABP. An important focus of hospitalists is to provide care improvement in a way that addresses both patient and hospital needs. It is essential that the hospitalist provides best possible patient care, including adherence to quality measures, optimizing the patient's hospital length of stay, and arranging adequate post-discharge care in an effort to prevent readmission and provide appropriate ongoing outpatient care.


Subject(s)
Anti-Bacterial Agents/therapeutic use , Hospitalists , Hospitalization , Pneumonia, Bacterial/drug therapy , Community-Acquired Infections/diagnosis , Community-Acquired Infections/drug therapy , Community-Acquired Infections/microbiology , Diagnosis, Differential , Drug Resistance, Bacterial , Drug Therapy, Combination , Hospitalists/standards , Humans , Pneumonia, Bacterial/diagnosis , Pneumonia, Bacterial/microbiology , Pneumonia, Pneumococcal/diagnosis , Pneumonia, Pneumococcal/drug therapy , Pneumonia, Pneumococcal/microbiology , Pneumonia, Staphylococcal/diagnosis , Pneumonia, Staphylococcal/drug therapy , Pneumonia, Staphylococcal/microbiology , Quality Indicators, Health Care , Severity of Illness Index , Treatment Outcome
4.
J Hosp Med ; 6(5): E1-5, 2011 May.
Article in English | MEDLINE | ID: mdl-21661096

ABSTRACT

There are many controversial topics relating to renal disease in hospitalized patients. The aim of this review is to shed light on some important and often debated issues. Hypothyroidism, unlike myxedema, is not a cause of hyponatremia (although it can be sometimes seen in conjunction with the latter) and additional investigations should be done to determine its etiology. Sodium bicarbonate is effective for treatment of hyperkalemia primarily by enhancing renal potassium elimination rather than by translocating potassium into cells. Acetaminophen can be a cause of metabolic acidosis by causing 5-oxoprolinuria. Furosemide (and sulfa containing diuretics) can safely be used in patients with an allergy to sulfa-containing antibiotics (SCA).


Subject(s)
Kidney Diseases/metabolism , Kidney Diseases/therapy , Nephrology/methods , Animals , Humans , Hyperkalemia/complications , Hyperkalemia/metabolism , Hyperkalemia/therapy , Hyponatremia/complications , Hyponatremia/metabolism , Hyponatremia/therapy , Hypothyroidism/complications , Hypothyroidism/metabolism , Hypothyroidism/therapy , Kidney Diseases/complications , Nephrology/trends
SELECTION OF CITATIONS
SEARCH DETAIL
...